Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Regression Toward the Mean01:52

Regression Toward the Mean

Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when researchers try to extrapolate results...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Statistical considerations for sex inclusion in clinical studies.

Annals of epidemiology·2026
Same author

Treatment of Intractable Cancer Pain with Resiniferatoxin - An Interim Study.

NEJM evidence·2025
Same author

MRISegmenter: A Fully Accurate and Robust Automated Multiorgan and Structure Segmentation Tool for T1-weighted Abdominal MRI.

Radiology·2025
Same author

Assessing the Reliability of Pancreatic CT Imaging Biomarkers for Diabetes Prediction: A Dual Center Retrospective Study.

Academic radiology·2025
Same author

Do Caregivers Value the New Antiamyloid Treatments for Alzheimer's Disease More Than Home-Based Care?

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry·2024
Same author

MRISegmentator-Abdomen: A Fully Automated Multi-Organ and Structure Segmentation Tool for T1-weighted Abdominal MRI.

ArXiv·2024
Same journal

Methods for incorporating test result information within the high-dimensional propensity score framework: application in UK electronic health record data.

BMC medical research methodology·2026
Same journal

Sparse multi-way DMDC for longitudinal classification in high dimension low sample size data.

BMC medical research methodology·2026
Same journal

Tree-based exploratory identification of predictive biomarkers in non-randomized data.

BMC medical research methodology·2026
Same journal

Comparative evaluation of interrupted time series analytical methods for healthcare quality improvement research: a Monte Carlo simulation study.

BMC medical research methodology·2026
Same journal

Methodological advances in claims-based dementia algorithms: integrating medication and clinical data for medicare populations.

BMC medical research methodology·2026
Same journal

An interpretable XGboost algorithm for predicting 30-day mortality in acute pancreatitis using routine biomarkers.

BMC medical research methodology·2026
See all related articles

Related Experiment Videos

Translating treatment effects between correlated endpoints.

Nusrat Rabbee1

  • 1Statistical Innovation and Multimodal Evidence Synthesis, Quantitative and Statistical Sciences, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill Road, Tarrytown, NY, 10591, USA. nusrat.rabbee@regeneron.com.

BMC Medical Research Methodology
|May 28, 2026
PubMed
Summary
This summary is machine-generated.

This study introduces the Stacked Linear Mixed Effects Model (SLIM) for unbiasedly translating treatment effects between correlated clinical endpoints. SLIM provides accurate quantitative associations, improving evidence synthesis in translational science.

Keywords:
Evidence SynthesisMeta-AnalysisMultilevel modelingMultiple Correlated EndpointsStacked Linear Mixed-Effects ModelSurrogate Endpoint

Related Experiment Videos

Area of Science:

  • Translational Science
  • Biostatistics
  • Clinical Research Methodology

Background:

  • Clinical researchers require methods to predict changes in one endpoint based on alterations in another.
  • Existing meta-analytic techniques often yield biased estimates or lack explicit translational coefficients.

Purpose of the Study:

  • To develop a novel multivariate random-effects meta-analysis framework for deriving the Expected Translational Association (η).
  • To provide unbiased estimates and reliable confidence coverage for translating treatment effects across correlated endpoints.

Main Methods:

  • Implementation of a stacked multivariate random-effects meta-analysis, termed SLIM (Stacked Linear Mixed Effects Model).
  • Simultaneous fitting of all correlated endpoints using their shared variance-covariance structure.
  • Validation through extensive simulations and application to the abdominal aortic aneurysm (AAA) dataset.

Main Results:

  • SLIM demonstrated near-zero bias and nominal coverage across various simulation scenarios.
  • The Daniels-Hughes approach showed significant bias, particularly with measurement error in covariates.
  • SLIM quantified translational associations for AAA growth-rate and rupture-risk endpoints, enabling "what if" analyses.

Conclusions:

  • SLIM offers a rigorous and transparent foundation for evidence synthesis in translational science.
  • The framework provides unbiased estimates for translating treatment effects across correlated endpoints.
  • This approach enhances quantitative biomarker-outcome analyses and improves clinical research decision-making.